Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

PMID:
24881730
[PubMed - indexed for MEDLINE]
2.

Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.

Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL; The Finnprostate Group.

Scand J Urol. 2014 Mar 31. [Epub ahead of print]

PMID:
24679247
[PubMed - as supplied by publisher]
3.

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

Eur Urol. 2013 Jan;63(1):111-20. doi: 10.1016/j.eururo.2012.07.040. Epub 2012 Jul 27.

PMID:
22857983
[PubMed - indexed for MEDLINE]
4.

Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death.

Huang RC, Auvinen A, Hakama M, Tammela TL, Ala-Opas M, Leppilahti M, Vornanen T, Chen HH.

Health Expect. 2012 Jul 19. doi: 10.1111/j.1369-7625.2012.00802.x. [Epub ahead of print]

PMID:
22809163
[PubMed - as supplied by publisher]
5.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C; SPCG-13.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):303-7.

PMID:
22546837
[PubMed - indexed for MEDLINE]
6.

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.

PMID:
22498230
[PubMed - indexed for MEDLINE]
7.

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group.

Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.

PMID:
22189383
[PubMed - indexed for MEDLINE]
8.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
[PubMed - indexed for MEDLINE]
9.

The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy.

Visapää H, Hotakainen K, Lundin J, Ala-Opas M, Stenman UH.

Urol Int. 2010;84(4):378-81. doi: 10.1159/000296302. Epub 2010 Mar 17.

PMID:
20299777
[PubMed - indexed for MEDLINE]
10.

Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.

Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A.

Int J Cancer. 2010 Oct 1;127(7):1650-9. doi: 10.1002/ijc.25165.

PMID:
20073066
[PubMed - indexed for MEDLINE]
11.

False-positive screening results in the Finnish prostate cancer screening trial.

Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A.

Br J Cancer. 2010 Feb 2;102(3):469-74. doi: 10.1038/sj.bjc.6605512. Epub 2010 Jan 5.

PMID:
20051951
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.

Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A.

Br J Cancer. 2009 Sep 1;101(5):843-8. doi: 10.1038/sj.bjc.6605188. Epub 2009 Aug 4.

PMID:
19654575
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors.

Mikkola A, Aro J, Rannikko S, Ruutu M; Finnprostate Group.

Scand J Urol Nephrol. 2009;43(4):265-70. doi: 10.1080/00365590902836500.

PMID:
19382005
[PubMed - indexed for MEDLINE]
14.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

PMID:
19297566
[PubMed - indexed for MEDLINE]
Free Article
15.

Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy.

Giordano S, Taskinen S, Sankila A, Ala-Opas M.

Scand J Urol Nephrol. 2008;42(4):392-4. doi: 10.1080/00365590701871575.

PMID:
19230174
[PubMed - indexed for MEDLINE]
16.

Biological aggressiveness of prostate cancer in the Finnish screening trial.

Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T, Määttänen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P.

Int J Cancer. 2009 Feb 1;124(3):547-52. doi: 10.1002/ijc.23873.

PMID:
19004023
[PubMed - indexed for MEDLINE]
17.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
[PubMed - indexed for MEDLINE]
18.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.

Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.

PMID:
18432528
[PubMed - indexed for MEDLINE]
19.

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Raitanen MP; FinnBladder Group.

World J Urol. 2008 Feb;26(1):45-50. doi: 10.1007/s00345-007-0230-3. Epub 2008 Jan 8.

PMID:
18180926
[PubMed - indexed for MEDLINE]
20.

A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.

Mikkola AK, Aro JL, Rannikko AS, Ruutu ML; Finnprostate Group.

BJU Int. 2008 May;101(9):1090-5. Epub 2007 Dec 5.

PMID:
18070186
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk